Related Experiment Videos
[Immunotherapy of type 1 diabetes]
La Revue Du Praticien
|May 1, 1992
Summary
Type 1 diabetes results from autoimmune destruction of B islet cells, driven by T lymphocytes. Interventions can halt B cell destruction even in advanced diabetes, with future therapies targeting early detection and specific immune agents.
Area of Science:
- Immunology
- Endocrinology
- Autoimmune Diseases
Background:
- Insulin-dependent diabetes mellitus (Type 1 diabetes) is a chronic autoimmune condition targeting pancreatic B islet cells.
- The autoimmune process begins years before clinical hyperglycemia becomes apparent.
- Autoreactive T lymphocytes play a critical role in the pathogenesis of B cell destruction.
Purpose of the Study:
- To review the autoimmune basis of Type 1 diabetes.
- To discuss the potential of immunointervention strategies.
- To highlight future therapeutic directions in Type 1 diabetes management.
Main Methods:
- Review of experimental evidence on T lymphocyte roles.
- Analysis of immunointervention studies, including cyclosporin treatment.
- Discussion of emerging diagnostic markers and targeted therapies.
Main Results:
- Immunointervention, such as with cyclosporin, can halt B cell destruction even in overt diabetes.
- Early detection of prediabetes through genetic and immunological markers is feasible.
- Specific agents like monoclonal antibodies and immunotoxins show therapeutic promise.
Conclusions:
- Type 1 diabetes is a progressive autoimmune disease with a long preclinical phase.
- Therapeutic strategies can successfully intervene in B cell destruction.
- Future approaches emphasize early detection and targeted immunotherapies for Type 1 diabetes.